Desentum
Finland - EspooBiotechnology
Focus: Desentum is a Finnish biotechnology company focused on developing monoclonal antibodies for long-term allergy protection. Founded in 2011 and publicly listed, the company operates at a specialized niche within the allergy immunotherapy space.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Desentum
AI assessmentNot HiringNo open roles listed right now. Follow Desentum to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
DM-101
Birch Pollen AllergyClinical Trials (1)
NCT04266028Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
Phase 1Help build intelligence for Desentum
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.